FDA approves first Nanobody-based medicine for adults with aTTP10 Feb 2019
Cablivi is the first US approval for Sanofi's new rare blood disorders franchise.
The FDA has approved Cablivi (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is the first FDA approved therapy specifically indicated for the treatment of aTTP.
"The US approval of Cablivi provides a much-needed treatment option for people facing this challenging disease. There have been limited medicines available to treat aTTP until now," says Olivier Brandicourt, Chief Executive Officer, Sanofi. "Cablivi marks the first US approval in our newly formed rare blood disorders franchise, and we look forward to continuing to provide important medicines for people living with these very serious diseases."
Cablivi targets von Willebrand factor (vWF), a protein in the blood involved in hemostasis. It is designed to inhibit the interaction between vWF and platelets. Cablivi is an anti-vWF Nanobody and Sanofi's first Nanobody-based medicine to receive approval in the US. Nanobodies are a novel class of proprietary therapeutic proteins based on single-domain antibody fragments that contain the unique structural and functional properties of naturally-occurring heavy chain only antibodies.
Cablivi received FDA Fast Track designation and was evaluated under Priority Review, which is reserved for medicines that represent significant improvements in safety or efficacy in treating serious conditions.
SGS to conduct its first malaria human challenge trial in Belgium
13 Feb 2019
The advanced candidate compound undergoing the trial has demonstrated potential to target malaria parasites before they have a chance to establish the symptoms of malaria.Read more
Post-EU FMD deadline - 'business as usual'?
12 Feb 2019
Partner connectivity will be an immediate and ongoing challenge beyond the deadline and several pharma companies are likely to break agreements with current suppliers through breach of contract clauses.Read more
BASF opens Application Technology Laboratory for personal care in Nigeria
11 Feb 2019
Local competence in application and formulation technology for sub-Saharan African personal care market.Read more
Pharmapack Europe 2019 Award Winners
7 Feb 2019
Awards showcased a wide range of industry-changing discoveries in drug delivery, packaging and automation.Read more
Brexit - the EU FMD's painful problem
7 Feb 2019
Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.Read more
New series of advanced freeze dryers
6 Feb 2019
The LyoConstellation series allows the development of highly aggressive cycles and the mapping of the furthest reaches of theoretical design space for a formulation.Read more
Hitachi Chemical to acquire apceth Biopharma
5 Feb 2019
Acquisition will strengthen Hitachi's presence in the second-largest cell and gene therapy market in the world.Read more
FDA approves first generic Advair Diskus
4 Feb 2019
Mylan's Wixela Inhub is the first FDA-approved therapeutically equivalent generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or COPD.Read more
Sartorius joins the community of the National Institute for Innovation in Manufacturing Biopharmaceuticals
3 Feb 2019
Company hopes to contribute substantially to further optimizing and accelerating the current manufacturing processes in the biopharmaceutical industry.Read more
Particle Sciences partners with Encube Ethicals to develop novel vaginal rings
31 Jan 2019
The partnership will focus on rings for the administration of existing approved drugs, improving drug effectiveness and patient compliance.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation